Therapeutic plasma exchange as an intervention for gemtuzumab ozogamicin impaired hemoglobin scavenging: A case and systematic review
Journal of Clinical Apheresis · 2024
DOI: 10.1002/jca.22116 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Clinical Apheresis, 2024. Verfasst von Brian D Adkins und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Gemtuzumab, Plasma Exchange, Hemoglobins. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Gemtuzumab ozogamicin (GO) is a CD33 monoclonal antibody‐drug conjugate currently in use to treat myeloid malignancies. A unique adverse effect of this medication is destruction of CD33 positive macrophages resulting in reduced clearance of free hemoglobin leading to grossly red plasma. This build‐up of free hemoglobin can potentially lead to end organ damage and prevent performance of clinically necessary laboratory evaluation. We present a case of a pediatric patient who developed this adverse effect and was successfully treated with therapeutic plasma exchange (TPE). We also present results from a systematic review of the medical literature and share data from a query of the United States Food and Drug Administration (FDA) Adverse Event Reporting system for GO‐related hemoglobin scavenging impairment. Among reported cases, patients undergoing TPE and those receiving steroids had improved outcomes. Practitioners should be aware of this rare drug side‐effect and the potential utility of TPE for these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Children's Health System, Dallas, Texas, USA.
- Division of Hematology and Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
ORCID-Profile: Brian D Adkins
Zitieren
APA
Adkins, B. D., Noland, D. K., Slone, T., & Sadanand, A. (2024). Therapeutic plasma exchange as an intervention for gemtuzumab ozogamicin impaired hemoglobin scavenging: A case and systematic review. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.22116
Vancouver
Adkins BD, Noland DK, Slone T, Sadanand A. Therapeutic plasma exchange as an intervention for gemtuzumab ozogamicin impaired hemoglobin scavenging: A case and systematic review. Journal of Clinical Apheresis. 2024. doi:10.1002/jca.22116
BibTeX
@article{Adkins2024,
author = {Adkins, Brian D and Noland, Daniel K and Slone, Tamra and Sadanand, Arhanti},
title = {Therapeutic plasma exchange as an intervention for gemtuzumab ozogamicin impaired hemoglobin scavenging: A case and systematic review},
journal = {Journal of Clinical Apheresis},
year = {2024},
doi = {10.1002/jca.22116}
}
EUVIMED